Company profile: Targanta Therapeutics
1.1 - Company Overview
Company description
- Provider of innovative antibiotics and antibacterial therapies for serious infections treated or acquired in hospitals and other institutional settings, including oritavancin, an intravenous bactericidal agent for Gram-positive infections with Phase III trials for complicated skin and skin structure infections; antibacterial pro-drugs for osteomyelitis; and a drug discovery platform that mimics strategies devised by bacterial viruses to target druggable bacterial mechanisms.
Products and services
- Oritavancin: Clinical-stage intravenous bactericidal antibiotic against Gram-positive infections, completed Phase III trials for treating complicated skin and skin structure infections in hospital and institutional settings
- Drug Discovery Platform: Virus-mimicking antibacterial discovery system targeting druggable bacterial mechanisms to architect agents for serious infections treated or acquired in hospitals and other institutional settings
- Antibacterial pro-drugs for osteomyelitis: Bone-targeted compounds coupling potent antibiotics to bone targeting moieties, engineered for treatment and prevention of osteomyelitis
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Targanta Therapeutics
NRx Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage therapeutics targeting central nervous system disorders and pulmonary diseases, with investigational products including NRX-101 for suicidal bipolar depression (Phase 3), chronic pain (Phase 2), and PTSD (Phase 2), and NRX-100 (IV ketamine) for severe bipolar depression post stabilization from a suicidal crisis (Phase 3).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NRx Pharmaceuticals company profile →
Diagnostic Hybrids
HQ: United States
Website
- Description: Provider of cellular and molecular diagnostic kits and systems for detecting respiratory diseases, herpes infections, thyroid function, and other disease markers. Offers the D3 FastPoint L-DFA influenza A/B identification kit; Vitros Integrated, Chemistry, and Immunoassay Systems with broad, waterless testing menus; Ortho Vision Swift analyzer for automated donor typing; and Lyra real-time PCR assays that simplify sample processing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Diagnostic Hybrids company profile →
Durata Therapeutics
HQ: United States
Website
- Description: Provider of late-stage clinical development of novel antibiotics for infectious diseases, focused on Vicuron’s antibiotic.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Durata Therapeutics company profile →
ProStrakan
HQ: United Kingdom
Website
- Description: Provider of specialty pharmaceutical development and commercialisation of prescription medicines for unmet therapeutic needs in major markets; headquartered in Scotland with more than 300 employees and commercial operations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full ProStrakan company profile →
HilleVax
HQ: United States
Website
- Description: Provider of novel vaccine development and commercialization, focused on HIL-214, a bivalent GI.1/GII.4 virus-like particle (VLP) vaccine candidate in development to prevent moderate-to-severe acute gastroenteritis caused by norovirus infection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full HilleVax company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Targanta Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Targanta Therapeutics
2.2 - Growth funds investing in similar companies to Targanta Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Targanta Therapeutics
4.2 - Public trading comparable groups for Targanta Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →